INTRODUCTION {#s1}
============

Total Anomalous Pulmonary Venous Return (TAPVR) (OMIM:%106700) is one type of cyanotic Congenital Heart Defects (CHD), in which none of the pulmonary veins connect to the left atrium and are malpositioned to the systemic venous circulation \[[@R1]\] (Figure [1A, 1B](#F1){ref-type="fig"}). TAPVR characterized by cardiac function deterioration including cyanosis, pulmonary hypertension, dyspnea, pulmonary edema, congestive heart failure affects 1 in 15,000 live births and 48.8% of them will die without surgery before the age of 1 \[[@R2]\]. Although TAPVR generally presents significant fatality rate, the pathogenesis is still vague and become hot research spot.

![CT angiography in a 5-month-old girl with supracardiac total anomalous pulmonary venous connection (TAPVC) and unrestrictive ASD\
Multidetector CT angiography oblique coronal image (**A**) and volume rendered image (**B**) shows four individual pulmonary veins joining in a retrocardiac venous confluence and draining into the left innominate vein (LIV) via a vertical vein (VV). ASD: atrial septal defect; PV: pulmonary vein; SVC: superior vena cava; RIPV: right inferior pulmonary vein; RSPV: right superior pulmonary vein; LSPV: left superior pulmonary vein; LIPV: left inferior pulmonary vein; LIV: left innominate vein.](oncotarget-08-27812-g001){#F1}

In 1960, Neill *et al*. described the first case that TAPVR in 'scimitar syndrome' \[[@R3]\]. Then, TAPVR has been associated with GATA binding protein 4 (*GATA4*), Zic family member 3 (*ZIC3*), and Gap junction protein and alpha 1 (*GJA1*) \[[@R4]\]. After a de novo 10;21 balanced translocation was reported, Cinquetti *et al*. defined *ANKRD1* as a possible candidate gene for TAPVR in 2008 \[[@R5]\]. Bleyl et al established a locus for TAPVR at 4p13-q12 \[[@R6]\] and found the *PDGFRA* as a driver gene in the further detailed research \[[@R7]\]. A non-synonymous variant in retinol binding protein 5 (RBP5) by Whole genome sequence (WGS) was analysised in 2 TAPVR patients recently \[[@R8]\]. Nevertheless, the contribution of known genes above was still limited to investigate the genetic cause. Therefore, we applied WES to the investigation of the genetic cause in 6 sporadic TAPVR cases and 81 non-TAPVR controls. We performed independent replication on additional 12 TAPVR patients by Sanger sequencing to identify the possible genetic variants.

RESULTS {#s2}
=======

Gene classification {#s2_1}
-------------------

After filtered through Public and in-house database, genes were classified referring to ACMG standards and guidelines \[[@R9]\] as follows: Category I genes were 15 TAPVR Pathogenic or likely Pathogenic Genes. ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}); Category II genes were TAPVR associated Genes containing 221 human cardiac development related genes from gene ontology (GO) ([Supplementary Table 4](#SD2){ref-type="supplementary-material"}); Category III genes were unknown genes have not been reported previously. Correspondingly, Part I variants were in Category I genes. Part II variants were recurrent ones in Category II genes. Part III variants were not located in Category I genes and low frequency in the 1000 Genomes, Exome Sequencing Project (ESP) and the Exome Aggregation Consortium (ExAC, version 0.3).

Genetic findings {#s2_2}
----------------

We sequenced six sporadic TAPVR cases with mean coverage of 77-fold (\~ 8.33 GB Raw data yield per individual with paired-end, 100bp reads) ([Supplementary Table 5](#SD1){ref-type="supplementary-material"}). About 19,000 (range from 18824 to 19301) primary variants with high quality were identified per individual with standard GATK-haplotype calling process. Mutation screening was carried out according to American College of Medical Genetics (ACMG) criteria guidelines: (i) UTR, synonymous, intronic variants removed; (ii) variants with minor allele frequency (MAF) \< 1% from dbSNP 135, 1000 Genomes, ESP and ExAC; (iii) variants completely absent from 81 controls. After filtering, we used a combined strategy to identify potentially causal variants as follows: (i) Loss of function (LOF) variants or not; (ii) Allele frequency in the population; (iii) Homozygous or heterozygous mutations; (iv) Recurrence of the variants in different gene classification \[[@R9]\]. Finally, all the variants were divided into three Parts according to the possibility of pathogenic \[[@R10]\]. In Part I variants, we found two heterozygous missense SNVs: *ACVRL1*(NM_000020.2): c.C652T, p.R218W and *SMAD9*(NM_001127217): c.C743A, p.T248K in Patient 5; In Part II variants, *SGCD*(NM_172244): c.C717G, p.D239E was recurrent heterozygous missense variant in Patient 5, 6; In Part III variants, remaining variants were mainly referring to 62 LOF variants with MAF \< 0.1% ([Supplementary Table 6](#SD3){ref-type="supplementary-material"}). (Figure [2](#F2){ref-type="fig"})

![Variant filtration workflow\
Abbreviations are as follows: MAF, minor allele frequency; SNVs, single nucleotide variants; UTR, untranslated region.](oncotarget-08-27812-g002){#F2}

Functional prediction {#s2_3}
---------------------

Firstly, mutational impacts in Part I or Part II variants were predicted from tools including SIFT, Polyphen2 and MutationTaster (Table [1](#T1){ref-type="table"}). Prediction Scores of *ACVRL1*: c.C652T with high scores indicated probably or possibly damaging. However, the mutations in *SGCD* and *SMAD9* were predicted as ''benign''. Additionally, Part III variants were predicted by ToppGene (Table [2](#T2){ref-type="table"}). Finally, to quantify the functional relationship, 15 genes from Category I and 14 genes from Category II and Category III genes by ToppGene *p* \< 0.05 were visualized using STRING10 (Figure [3](#F3){ref-type="fig"}).

###### List of selected candidate variants in Category I and Category II genes

  Categories   Gene symbol   Position^a^   Chr.   Function            Ref   Alt   Protein change   SNP           ESP5400 MAF ESP   1kg2010 MAF 1000 Genomes   ExAC MAF   SIFTb   PolyPhen2c   Mutation Taster^d^
  ------------ ------------- ------------- ------ ------------------- ----- ----- ---------------- ------------- ----------------- -------------------------- ---------- ------- ------------ --------------------
  I            SMAD9         37441448      13     Nonsynonymous SNV   C     A     T248K            rs79733377    0.07%             0.86%                      0.15%      No      No           No
  I            ACVRL1        52308249      12     Nonsynonymous SNV   C     T     R218W            rs199874575   0.01%             0.02%                      0.04%      Yes     Pb           Yes
  II           SGCD          156184733     5      Nonsynonymous SNV   C     G     D239E            rs180898690   --                0.24%                      0.10%      No      No           No

Abbreviations are as follows: Chr., chromosome; MAF, minor allele frequency.

^a^Human genome build 37/hg19.

^b^SIFT: Yes, damaging; No, tolerated.

^c^PolyPhen: Pb, probably damaging; Ps, possibly damaging; No, benign.

^d^MutationTaster: yes, disease causing; No, polymorphism.

###### 14 genes of Category II and Category III genes by ToppGene p \< 0.05

  Rank   Gene Symbol   Gene Id   Average Score   Overall *p* Value
  ------ ------------- --------- --------------- -------------------
  1      *HLTF*        6596      0.5327          0.0062
  2      *CTNNA3*      29119     0.5252          0.0106
  3      *CD80*        941       0.5720          0.0127
  4      *DNAAF3*      352909    0.4817          0.0197
  5      *NEDD4L*      23327     0.4399          0.0202
  6      *MELK*        9833      0.4253          0.0216
  7      *TBCE*        6905      0.3860          0.0241
  8      *FNIP1*       96459     0.4714          0.0286
  9      *OAZ3*        51686     0.5132          0.0289
  10     *TEP1*        7011      0.4142          0.0289
  11     *PDE3A*       5139      0.3717          0.0302
  12     *DIDO1*       11083     0.4533          0.0353
  13     *CLCNKB*      1188      0.2675          0.0390
  14     *KIF23*       9493      0.2973          0.0489

63 genes were set as test genes, while 15 TAPVR Pathogenic or likely Pathogenic genes were set as training genes. The results showed 14 genes were highly correlated with TAPVR, indicating that the SNVs in these genes may be deleterious.

![STRING pathway analysis plot (confidence score = 0.5)\
Network included 15 genes previously associated to TAPVR and 14 candidate genes highlighted by ToppGene analysis. The confidence view showed that *NEDD4L* associated with *PDGFRA* (combined association score = 0.819), *CD80* associated with *CD8A* (combined association score = 0.900) and *OAZ3* with *SMAD1* (combined association score = 0.566).](oncotarget-08-27812-g003){#F3}

Validation of variants {#s2_4}
----------------------

In the validation stage, the identified exome sequencing candidate variants were confirmed by PCR-based Sanger sequence in 6 discovery TAPVR cases and another 12 validation TAPVR cases (Figure [4](#F4){ref-type="fig"}). Primers of Sanger sequencing were listed ([Supplementary Table 7](#SD1){ref-type="supplementary-material"}).

![Sanger chromatograms of mutations\
The mutation in *SGCD* (c.C717G) was detected in 2 discovery cases (**A**, **B**) and 1validation cases (**C**). The mutations in *ACVRL1* (c.C652T) *and SMAD9* (c.C743A) were also replicated by Sanger re-sequencing (**D, E**).](oncotarget-08-27812-g004){#F4}

DISCUSSION {#s3}
==========

In our study, 18 TAPVR cases and 81 non-TAPVR controls were included to reveal the genetic etiology of TAPVR in Chinese population. We screened out candidate pathogenic variants in 6 TAPVR patients, and replicated these variants in another 12 TAPVR cases. Further results were annotated and classified into several ranks based on the functional impacts. We provided evidence for *ACVRL1* as a known causative gene and for *SGCD* as candidate genes for TAPVR. Although potential disease-driving regions or genes (e.g., 4p13-q12, *ANKRD1*, etc.) in previous studies were detected, we only found few intron or UTR variants in *ANKRD1* or *PDGFRA* in our data. It may be ethnic heterogeneity because the previous studies mainly focused on Utah family rather than Chinese family TAPVR.

A rare missense mutation in *ACVRL1* (c.C652T, p.R218W) was identified as a causal mutation for TAPVR. Activin receptor like kinase 1 (*ACVRL1*) is a type I cell-surface receptor for the TGF-beta superfamily of ligands, located on chromosome 12q13. Johnson et al. \[[@R11]\] noted that the high expression of *ACVRL1* in highly vascularized tissues such as lung and placenta. More than 225 mutations in *ACVRL1* have been reported in HGMD (The Human Gene Mutation Database). Notably, C652T was reported in vein of Galen aneurysmal malformation (VGAM) \[[@R12]\]. T649G (p.T217G), G650A (p.W217X) \[[@R13]--[@R15]\] and G656A (p.G219H) \[[@R16]\] in nearby were also critical for HHT1 or pulmonary hypertension. It is interesting that we aimed at finding new TAPVR gene, but WES ultimately led to the identification a known causal variant in a different but related disease. Pulmonary hypertension is a rare lung disorder in which the arteries that carry blood from the heart to the lungs become narrowed, making it difficult for blood to flow through the vessels. All of the TAPVR patients sequenced suffered from pulmonary hypertension and mostly recovered after surgery. Therefore, we could infer that mutations in *ACVRL1* may account for TAPVR.

A recurrent mutation in *SGCD* (c.C717G, p.D239E) was detected, which coded for the dystrophin-glycoprotein complex (*DGC*). Mutations of *SGCD* were accompanied with dilated cardiomyopathy and muscular dystrophy in Caucasians, although not previously reported on TAPVR \[[@R17], [@R18]\]. Particularly, the recent study confirmed that the c.S151A mutation in *SGCD* causes a mild, subclinical cardiomyopathy phenotype \[[@R19]\]. Notably, they were found in 2/6 discovery patients, 1/12 validation patients and not in 81 control samples. Therefore, C717G were proven more responsible for TAPVR.

In contrast to previous studies \[[@R5], [@R7]\], whole-exome sequencing has already arrived in the clinic and was a powerful tool to investigate candidate mutations for rare diseases. The FORGE (Finding of Rare Disease Genes) Canada Consortium studied 264 disorders from the 371 submitted and identified disease-causing variants for 146 disorders over a 2-year period \[[@R20]\]. Several limitations in our study should be concerned including sample size. However, considering the low incidence of TAPVAR in population, our study is still a good attempt. In addition, analysis only focused on variations in coding regions, information for other regions were missing (such as introns, UTR or intergenic regions) \[[@R21]\]. Taken together, our findings need to be further validated in functional studies or large well-designed population-based studies in the future.

In conclusion, our study was the first attempt to dissect the etiology of TAPVR using whole-exome sequencing strategy in Chinese population. The results will provide important value to translate mutations detected by whole-exome sequencing to clinical diagnosis.

MATERIALS AND METHODS {#s4}
=====================

Subjects {#s4_1}
--------

All of the TAPVR children were recruited from Nanjing Children\'s Hospital, Nanjing Medical University. The discovery cohort consisted of 6 cases (mean age: 5 months (range 1--11 months); gender: 1 female, 5 male) ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). The replication cohort consisted of 12 cases (mean age: 27 months (range 1--152 months); gender: 8 female, 4 male). All patients are Non-syndromic TAPVR with atrial septal defects (ASD) or pulmonary hypertension (PH). We performed Identity-by-descent (IBD) on 6 cases using PLINK 1.07 and confirmed no blood relationship on them ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}). All of patients were proved by echocardiography, 12-lead electrocardiography and surgery. An in-house control database, including 81 non-TAPVR individuals, were also performed WES. All subjects included in this study have written informed consent, and the study was approved by the institutional ethical committee of Nanjing Medical University. All methods and experimental protocols were approved by Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, and carried out in accordance with the approved guidelines.

Extraction of DNA {#s4_2}
-----------------

A DNA extraction procedure was carried out using a QIAamp™ DNA and Blood Mini kit Qiagen™) according to the manufacturer\'s protocols. Total DNA concentration and quantity were assessed by measuring absorbance at 260 nm with NanoDrop 2000c Spectrophotometer (Thermo Scientific™).

Library preparation and sequencing {#s4_3}
----------------------------------

Genomic DNA from whole blood (0.2 μg DNA) and was captured using the Agilent SureSelect Human All Exon v5 Kit. Input amounts were fragmented to a size range of 200 bp followed by end repair, adaptor ligation, and 11 PCR cycles. Appropriate amounts of enrichment DNA libraries were barcoded, pooled and loaded to lanes of a HiSeq Flow Cell, followed by 101 bp paired-end sequencing using Illumina HiSeq 1500 platform according to manufacturer\'s protocol.

Bioinformatics analysis {#s4_4}
-----------------------

For whole-exome sequencing (WES), image analysis and base calling were performed with CASAVA v1.8.2 using default parameters. The sequence reads were aligned to the hg19 reference sequence using BWA \[[@R22]\]. Picard tools were used to mark duplicates, and then multiple GATK tools (GATK LeftAlignIndels, IndelRealligner and Base Quality score recalibration) were applied to improve alignment accuracy. Variant discovery and genotype calling of single nucleotide variants (SNVs), insertions and deletions were performed on all individuals globally using the HaplotypeCaller modules of Genome Analysis Toolkit (GATK v2.8) \[[@R23]\]. Variant annotation process was performed using SnpEff, SnpSift (<http://snpeff.sourceforge.net>) and ANNOVAR(<http://annovar.openbioinformatics.org/en/latest/>). The Integrative Genomics Viewer (IGV)(<http://www.broadinstitute.org/igv>), a high-performance visualization tool, was used to check the variations manually according to genomic position \[[@R24]\].

PCR-based sanger resequencing {#s4_5}
-----------------------------

PCR Primers were designed for the target regions and were used to amplify these regions by PCR for Sanger resequencing. Mutations were validated according to the resulting data screened through Chromas 2.4.1 and Dnaman 6.0.

Functional annotation tools {#s4_6}
---------------------------

Widely used functional annotation tools for mutations were integrated together to evaluate the biological functions and further interactions: Transcriptome Ontology Pathway PubMed based prioritization of Genes (ToppGene, <http://toppgene.cchmc.org>) works by gene list enrichment analysis and candidate gene prioritization based on functional annotations and protein interactions network \[[@R25]\]; Search Tool for the Retrieval of Interacting Genes/Proteins (STRING, <http://string.embl.de>) generalizes access to protein interaction data, by integrating known and predicted interactions from a variety of sources \[[@R26]\].
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